Two University of Arizona Cancer Center researchers received a grant to spearhead a study to reduce stigma felt by lung cancer patients.
The National Comprehensive Cancer Network has published new NCCN Harmonized Guidelines for sub-Saharan Africa in Kigali, Rwanda.
Hospitals enrolled in the 340B program stand to lose up to $1.6 billion in Medicare Part B reimbursements through upcoming cuts to the drug pricing program, according to a final rule by the Centers for Medicare and Medicaid Services.
Trying to build a cancer center in the middle of a saturated market should be difficult enough.
Should Donald “Skip” Trump look up while talking to you on the phone, he might see deer roaming in the pine forest outside his office window.
FDA has approved Yescarta (axicabtagene ciloleucel), a genetically modified cell therapy, to treat adult patients with certain types of large B cell lymphoma who have not responded to or have relapsed after at least two other kinds of treatment.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following
Argos Therapeutics Inc. reported on an update on the interim analysis of data from the ongoing phase III ADAPT clinical trial evaluating Rocapuldencel-T for the treatment of metastatic renal cell carcinoma was presented by Robert Figlin, professor and chairman, division of hematology and oncology at Cedars Sinai Medical Center, and co-principal investigator of the ADAPT trial at the European Society for Medical Oncology 2017 Congress in Madrid.
Pfizer Inc. and Astellas Pharma Inc. announced the phase III PROSPER trial evaluating XTANDI (enzalutamide) plus androgen deprivation therapy versus ADT alone in patients with non-metastatic castration-resistant prostate cancer met its primary endpoint of improved metastasis-free survival.
A new Cleveland Clinic study underscores the importance of early detection and treatment of melanoma, the deadliest form of skin cancer.
